世界の先天性心疾患市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Congenital Heart Diseases Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z1538 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、先天性心疾患のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（低形成、閉塞性、中隔欠損症）、用途別市場規模（病院、外来手術センター、診断センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・先天性心疾患の市場動向 ・企業の競争状況、市場シェア ・先天性心疾患の種類別市場規模（低形成、閉塞性、中隔欠損症） ・先天性心疾患の用途別市場規模（病院、外来手術センター、診断センター、その他） ・先天性心疾患の北米市場規模2016-2027（アメリカ、カナダ） ・先天性心疾患のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・先天性心疾患のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・先天性心疾患の中南米市場規模2016-2027（メキシコ、ブラジル） ・先天性心疾患の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Abbott Laboratories、Eli Lilly、Ranbaxy Pharmaceutical） ・結論

Congenital diseases are disorders in a newborn due to certain genetic factors (and sometimes in association with the environment) that often results in malformations or underdeveloped organs. Congenital Heart Diseases (CHD) results in malformed or undeveloped heart that presents in a newborn with breathing and circulation disorders. According to Lancet medical journal, CHD caused death of 0.22 million individuals and newborns globally in the year 2010. CHD was earlier erroneously associated with premature births, the association has no direct correlation with all forms of CHD and is mainly one of the many factors that can cause it. The genetic factors causing CHD consist of chromosomal errors in fertilization and the following meiotic division, these include: large chromosomal defects in trisomal chromosomes; small chromosomal defects like microdeletion of long/short arm of chromosome and random/environmentally induced mutation of heart muscle cell proteins, or associated proteins etc. The environmental factors like rubella infections, thalidomide drugs, metals (lithium, lead, mercury, etc), chronic illness in the mother (systemic lupus, diabetes, phenylketonuria, etc). Embryological changes, hormonal changes in the mother and certain birth deficiencies can also cause CHD and other birth defects in children. Besides these, according to some medical research reports, maternal obesity increased the chances of CHD in newborns; obesity was shown to increase the risk of previously hidden genetic traits of CHD in the new born children of such obese mothers.
The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.

Market Analysis and Insights: Global Congenital Heart Diseases Market
The global Congenital Heart Diseases market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Congenital Heart Diseases market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Congenital Heart Diseases market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Congenital Heart Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Congenital Heart Diseases market.

Global Congenital Heart Diseases Scope and Market Size
Congenital Heart Diseases market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Congenital Heart Diseases market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Hypoplasia
Obstructive
Septal Defects

Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Abbott Laboratories
Eli Lilly

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Congenital Heart Diseases Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Hypoplasia
1.2.3 Obstructive
1.2.4 Septal Defects
1.3 Market by Application
1.3.1 Global Congenital Heart Diseases Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Congenital Heart Diseases Market Perspective (2016-2027)
2.2 Congenital Heart Diseases Growth Trends by Regions
2.2.1 Congenital Heart Diseases Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Congenital Heart Diseases Historic Market Share by Regions (2016-2021)
2.2.3 Congenital Heart Diseases Forecasted Market Size by Regions (2022-2027)
2.3 Congenital Heart Diseases Industry Dynamic
2.3.1 Congenital Heart Diseases Market Trends
2.3.2 Congenital Heart Diseases Market Drivers
2.3.3 Congenital Heart Diseases Market Challenges
2.3.4 Congenital Heart Diseases Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Congenital Heart Diseases Players by Revenue
3.1.1 Global Top Congenital Heart Diseases Players by Revenue (2016-2021)
3.1.2 Global Congenital Heart Diseases Revenue Market Share by Players (2016-2021)
3.2 Global Congenital Heart Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Congenital Heart Diseases Revenue
3.4 Global Congenital Heart Diseases Market Concentration Ratio
3.4.1 Global Congenital Heart Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Congenital Heart Diseases Revenue in 2020
3.5 Congenital Heart Diseases Key Players Head office and Area Served
3.6 Key Players Congenital Heart Diseases Product Solution and Service
3.7 Date of Enter into Congenital Heart Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Congenital Heart Diseases Breakdown Data by Type
4.1 Global Congenital Heart Diseases Historic Market Size by Type (2016-2021)
4.2 Global Congenital Heart Diseases Forecasted Market Size by Type (2022-2027)

5 Congenital Heart Diseases Breakdown Data by Application
5.1 Global Congenital Heart Diseases Historic Market Size by Application (2016-2021)
5.2 Global Congenital Heart Diseases Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Congenital Heart Diseases Market Size (2016-2027)
6.2 North America Congenital Heart Diseases Market Size by Type
6.2.1 North America Congenital Heart Diseases Market Size by Type (2016-2021)
6.2.2 North America Congenital Heart Diseases Market Size by Type (2022-2027)
6.2.3 North America Congenital Heart Diseases Market Size by Type (2016-2027)
6.3 North America Congenital Heart Diseases Market Size by Application
6.3.1 North America Congenital Heart Diseases Market Size by Application (2016-2021)
6.3.2 North America Congenital Heart Diseases Market Size by Application (2022-2027)
6.3.3 North America Congenital Heart Diseases Market Size by Application (2016-2027)
6.4 North America Congenital Heart Diseases Market Size by Country
6.4.1 North America Congenital Heart Diseases Market Size by Country (2016-2021)
6.4.2 North America Congenital Heart Diseases Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Congenital Heart Diseases Market Size (2016-2027)
7.2 Europe Congenital Heart Diseases Market Size by Type
7.2.1 Europe Congenital Heart Diseases Market Size by Type (2016-2021)
7.2.2 Europe Congenital Heart Diseases Market Size by Type (2022-2027)
7.2.3 Europe Congenital Heart Diseases Market Size by Type (2016-2027)
7.3 Europe Congenital Heart Diseases Market Size by Application
7.3.1 Europe Congenital Heart Diseases Market Size by Application (2016-2021)
7.3.2 Europe Congenital Heart Diseases Market Size by Application (2022-2027)
7.3.3 Europe Congenital Heart Diseases Market Size by Application (2016-2027)
7.4 Europe Congenital Heart Diseases Market Size by Country
7.4.1 Europe Congenital Heart Diseases Market Size by Country (2016-2021)
7.4.2 Europe Congenital Heart Diseases Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Congenital Heart Diseases Market Size (2016-2027)
8.2 Asia-Pacific Congenital Heart Diseases Market Size by Type
8.2.1 Asia-Pacific Congenital Heart Diseases Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Congenital Heart Diseases Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Congenital Heart Diseases Market Size by Type (2016-2027)
8.3 Asia-Pacific Congenital Heart Diseases Market Size by Application
8.3.1 Asia-Pacific Congenital Heart Diseases Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Congenital Heart Diseases Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Congenital Heart Diseases Market Size by Application (2016-2027)
8.4 Asia-Pacific Congenital Heart Diseases Market Size by Region
8.4.1 Asia-Pacific Congenital Heart Diseases Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Congenital Heart Diseases Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Congenital Heart Diseases Market Size (2016-2027)
9.2 Latin America Congenital Heart Diseases Market Size by Type
9.2.1 Latin America Congenital Heart Diseases Market Size by Type (2016-2021)
9.2.2 Latin America Congenital Heart Diseases Market Size by Type (2022-2027)
9.2.3 Latin America Congenital Heart Diseases Market Size by Type (2016-2027)
9.3 Latin America Congenital Heart Diseases Market Size by Application
9.3.1 Latin America Congenital Heart Diseases Market Size by Application (2016-2021)
9.3.2 Latin America Congenital Heart Diseases Market Size by Application (2022-2027)
9.3.3 Latin America Congenital Heart Diseases Market Size by Application (2016-2027)
9.4 Latin America Congenital Heart Diseases Market Size by Country
9.4.1 Latin America Congenital Heart Diseases Market Size by Country (2016-2021)
9.4.2 Latin America Congenital Heart Diseases Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Congenital Heart Diseases Market Size (2016-2027)
10.2 Middle East & Africa Congenital Heart Diseases Market Size by Type
10.2.1 Middle East & Africa Congenital Heart Diseases Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Congenital Heart Diseases Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Congenital Heart Diseases Market Size by Type (2016-2027)
10.3 Middle East & Africa Congenital Heart Diseases Market Size by Application
10.3.1 Middle East & Africa Congenital Heart Diseases Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Congenital Heart Diseases Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Congenital Heart Diseases Market Size by Application (2016-2027)
10.4 Middle East & Africa Congenital Heart Diseases Market Size by Country
10.4.1 Middle East & Africa Congenital Heart Diseases Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Congenital Heart Diseases Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Congenital Heart Diseases Introduction
11.1.4 Pfizer Revenue in Congenital Heart Diseases Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Details
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Congenital Heart Diseases Introduction
11.2.4 Abbott Laboratories Revenue in Congenital Heart Diseases Business (2016-2021)
11.2.5 Abbott Laboratories Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Congenital Heart Diseases Introduction
11.3.4 Eli Lilly Revenue in Congenital Heart Diseases Business (2016-2021)
11.3.5 Eli Lilly Recent Development
11.4 Ranbaxy Pharmaceutical
11.4.1 Ranbaxy Pharmaceutical Company Details
11.4.2 Ranbaxy Pharmaceutical Business Overview
11.4.3 Ranbaxy Pharmaceutical Congenital Heart Diseases Introduction
11.4.4 Ranbaxy Pharmaceutical Revenue in Congenital Heart Diseases Business (2016-2021)
11.4.5 Ranbaxy Pharmaceutical Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Congenital Heart Diseases Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Hypoplasia
Table 3. Key Players of Obstructive
Table 4. Key Players of Septal Defects
Table 5. Global Congenital Heart Diseases Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Congenital Heart Diseases Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Congenital Heart Diseases Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Congenital Heart Diseases Market Share by Regions (2016-2021)
Table 9. Global Congenital Heart Diseases Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Congenital Heart Diseases Market Share by Regions (2022-2027)
Table 11. Congenital Heart Diseases Market Trends
Table 12. Congenital Heart Diseases Market Drivers
Table 13. Congenital Heart Diseases Market Challenges
Table 14. Congenital Heart Diseases Market Restraints
Table 15. Global Congenital Heart Diseases Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Congenital Heart Diseases Market Share by Players (2016-2021)
Table 17. Global Top Congenital Heart Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Congenital Heart Diseases as of 2020)
Table 18. Ranking of Global Top Congenital Heart Diseases Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Congenital Heart Diseases Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Congenital Heart Diseases Product Solution and Service
Table 22. Date of Enter into Congenital Heart Diseases Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Congenital Heart Diseases Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Congenital Heart Diseases Revenue Market Share by Type (2016-2021)
Table 26. Global Congenital Heart Diseases Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Congenital Heart Diseases Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Congenital Heart Diseases Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Congenital Heart Diseases Revenue Market Share by Application (2016-2021)
Table 30. Global Congenital Heart Diseases Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Congenital Heart Diseases Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Congenital Heart Diseases Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Congenital Heart Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Congenital Heart Diseases Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Congenital Heart Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Congenital Heart Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Congenital Heart Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Congenital Heart Diseases Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Congenital Heart Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Congenital Heart Diseases Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Congenital Heart Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Congenital Heart Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Congenital Heart Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Congenital Heart Diseases Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Congenital Heart Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Congenital Heart Diseases Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Congenital Heart Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Congenital Heart Diseases Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Congenital Heart Diseases Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Congenital Heart Diseases Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Congenital Heart Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Congenital Heart Diseases Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Congenital Heart Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Congenital Heart Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Congenital Heart Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Congenital Heart Diseases Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Congenital Heart Diseases Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Congenital Heart Diseases Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Congenital Heart Diseases Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Congenital Heart Diseases Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Congenital Heart Diseases Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Congenital Heart Diseases Product
Table 65. Pfizer Revenue in Congenital Heart Diseases Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Abbott Laboratories Company Details
Table 68. Abbott Laboratories Business Overview
Table 69. Abbott Laboratories Congenital Heart Diseases Product
Table 70. Abbott Laboratories Revenue in Congenital Heart Diseases Business (2016-2021) & (US$ Million)
Table 71. Abbott Laboratories Recent Development
Table 72. Eli Lilly Company Details
Table 73. Eli Lilly Business Overview
Table 74. Eli Lilly Congenital Heart Diseases Product
Table 75. Eli Lilly Revenue in Congenital Heart Diseases Business (2016-2021) & (US$ Million)
Table 76. Eli Lilly Recent Development
Table 77. Ranbaxy Pharmaceutical Company Details
Table 78. Ranbaxy Pharmaceutical Business Overview
Table 79. Ranbaxy Pharmaceutical Congenital Heart Diseases Product
Table 80. Ranbaxy Pharmaceutical Revenue in Congenital Heart Diseases Business (2016-2021) & (US$ Million)
Table 81. Ranbaxy Pharmaceutical Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Key Data Information from Secondary Sources
Table 84. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Congenital Heart Diseases Market Share by Type: 2020 VS 2027
Figure 2. Hypoplasia Features
Figure 3. Obstructive Features
Figure 4. Septal Defects Features
Figure 5. Global Congenital Heart Diseases Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Ambulatory Surgical Centers Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Others Case Studies
Figure 10. Congenital Heart Diseases Report Years Considered
Figure 11. Global Congenital Heart Diseases Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Congenital Heart Diseases Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Congenital Heart Diseases Market Share by Regions: 2020 VS 2027
Figure 14. Global Congenital Heart Diseases Market Share by Regions (2022-2027)
Figure 15. Global Congenital Heart Diseases Market Share by Players in 2020
Figure 16. Global Top Congenital Heart Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Congenital Heart Diseases as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Congenital Heart Diseases Revenue in 2020
Figure 18. Global Congenital Heart Diseases Revenue Market Share by Type (2016-2021)
Figure 19. Global Congenital Heart Diseases Revenue Market Share by Type (2022-2027)
Figure 20. North America Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Congenital Heart Diseases Market Share by Type (2016-2027)
Figure 22. North America Congenital Heart Diseases Market Share by Application (2016-2027)
Figure 23. North America Congenital Heart Diseases Market Share by Country (2016-2027)
Figure 24. United States Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Congenital Heart Diseases Market Share by Type (2016-2027)
Figure 28. Europe Congenital Heart Diseases Market Share by Application (2016-2027)
Figure 29. Europe Congenital Heart Diseases Market Share by Country (2016-2027)
Figure 30. Germany Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Congenital Heart Diseases Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Congenital Heart Diseases Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Congenital Heart Diseases Market Share by Region (2016-2027)
Figure 40. China Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Congenital Heart Diseases Market Share by Type (2016-2027)
Figure 48. Latin America Congenital Heart Diseases Market Share by Application (2016-2027)
Figure 49. Latin America Congenital Heart Diseases Market Share by Country (2016-2027)
Figure 50. Mexico Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Congenital Heart Diseases Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Congenital Heart Diseases Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Congenital Heart Diseases Market Share by Country (2016-2027)
Figure 56. Turkey Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Congenital Heart Diseases Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Pfizer Revenue Growth Rate in Congenital Heart Diseases Business (2016-2021)
Figure 60. Abbott Laboratories Revenue Growth Rate in Congenital Heart Diseases Business (2016-2021)
Figure 61. Eli Lilly Revenue Growth Rate in Congenital Heart Diseases Business (2016-2021)
Figure 62. Ranbaxy Pharmaceutical Revenue Growth Rate in Congenital Heart Diseases Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

---